Caxton Associates LP Purchases Shares of 108,798 Kodiak Sciences Inc. (NASDAQ:KOD)

Caxton Associates LP purchased a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KODGet Rating) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 108,798 shares of the company’s stock, valued at approximately $831,000. Caxton Associates LP owned about 0.21% of Kodiak Sciences at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in KOD. BlackRock Inc. grew its holdings in shares of Kodiak Sciences by 20.5% in the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock valued at $26,526,000 after purchasing an additional 584,762 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Kodiak Sciences in the second quarter valued at approximately $4,136,000. Acadian Asset Management LLC acquired a new position in shares of Kodiak Sciences in the first quarter valued at approximately $3,603,000. Krensavage Asset Management LLC acquired a new position in shares of Kodiak Sciences in the first quarter valued at approximately $3,479,000. Finally, Monaco Asset Management SAM grew its holdings in shares of Kodiak Sciences by 518.1% in the second quarter. Monaco Asset Management SAM now owns 464,798 shares of the company’s stock valued at $3,551,000 after purchasing an additional 389,598 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KOD. The Goldman Sachs Group dropped their price objective on shares of Kodiak Sciences from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Thursday, November 10th. Citigroup dropped their price objective on shares of Kodiak Sciences from $8.00 to $6.00 in a report on Thursday, November 10th. Capital One Financial initiated coverage on shares of Kodiak Sciences in a report on Tuesday, November 15th. They issued an “overweight” rating and a $24.00 price objective for the company. Finally, Morgan Stanley lowered their price target on shares of Kodiak Sciences from $12.00 to $9.00 and set an “equal weight” rating for the company in a report on Monday, November 14th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Kodiak Sciences presently has an average rating of “Hold” and a consensus target price of $25.11.

Kodiak Sciences Stock Performance

Shares of NASDAQ:KOD opened at $7.19 on Friday. Kodiak Sciences Inc. has a twelve month low of $4.90 and a twelve month high of $19.27. The firm has a 50 day simple moving average of $7.25 and a 200-day simple moving average of $8.47.

Kodiak Sciences (NASDAQ:KODGet Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($1.47) earnings per share for the quarter, topping the consensus estimate of ($1.82) by $0.35. As a group, sell-side analysts predict that Kodiak Sciences Inc. will post -6.52 earnings per share for the current fiscal year.

Kodiak Sciences Company Profile

(Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Further Reading

Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KODGet Rating).

Institutional Ownership by Quarter for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.